Cargando…

Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial

BACKGROUND AND OBJECTIVES: Improved biomarkers of neuroprotective treatment are needed in progressive multiple sclerosis (PMS) to facilitate more efficient phase 2 trial design. The MS-STAT randomized controlled trial supported the neuroprotective potential of high-dose simvastatin in secondary prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Thomas E., Holdsworth, Katherine P., Nicholas, Jennifer M., Eshaghi, Arman, Katsanouli, Theodora, Wellington, Henrietta, Heslegrave, Amanda, Zetterberg, Henrik, Frost, Chris, Chataway, Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759719/ https://www.ncbi.nlm.nih.gov/pubmed/35031587 http://dx.doi.org/10.1212/NXI.0000000000001130

Ejemplares similares

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
por: Williams, Thomas, et al.
Publicado: (2022)

Neurofilaments in progressive multiple sclerosis: a systematic review
por: Williams, Thomas, et al.
Publicado: (2020)

The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapse‐onset multiple sclerosis
por: Williams, Thomas, et al.
Publicado: (2022)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
por: Strydom, Andre, et al.
Publicado: (2018)

Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis
por: Li, Vivien, et al.
Publicado: (2022)

Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation
por: Rosadas, Carolina, et al.
Publicado: (2021)

Neurofilament light in blood – What more is needed for clinical implementation in multiple sclerosis?
por: Zetterberg, Henrik
Publicado: (2020)

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
por: Weston, Philip S. J., et al.
Publicado: (2019)

Neurofilament light predicts neurological outcome after subarachnoid haemorrhage
por: Garland, Patrick, et al.
Publicado: (2021)

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease
por: Sánchez-Valle, Raquel, et al.
Publicado: (2018)

Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials
por: Williams, Thomas, et al.
Publicado: (2022)

Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kapoor, Mahima, et al.
Publicado: (2022)

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation
por: Gafson, Arie R., et al.
Publicado: (2022)

Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression
por: Thompson, Andrew Geoffrey Bourne, et al.
Publicado: (2018)

Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients
por: Page, Valerie J, et al.
Publicado: (2022)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique
por: Tur, Carmen, et al.
Publicado: (2021)

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
por: Chan, Dennis, et al.
Publicado: (2017)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome
por: Altmann, Patrick, et al.
Publicado: (2020)

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
por: Håkansson, Irene, et al.
Publicado: (2018)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study
por: Alagaratnam, Jasmini, et al.
Publicado: (2021)

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy
por: Weinhofer, Isabelle, et al.
Publicado: (2021)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study
por: Ehler, Johannes, et al.
Publicado: (2019)

Correction: The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study
por: Ehler, Johannes, et al.
Publicado: (2019)

Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
por: Shribman, Samuel, et al.
Publicado: (2020)

Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research
por: Rottlaender, Andrea, et al.
Publicado: (2015)

Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment
por: Iwan, Katharina, et al.
Publicado: (2022)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis
por: Aharoni, Rina, et al.
Publicado: (2021)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Neurofilament light and tau as blood biomarkers for sports-related concussion
por: Shahim, Pashtun, et al.
Publicado: (2018)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Neurofilament light chain in the vitreous humor of the eye
por: Subramanian, Manju L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mukv8bk2vojsvea77uvgc8igmo